Senior Vice President
Enzyvant Therapeutics, Inc.
Dr. Kevin Healy is a Senior Vice President of Regulatory Affairs, Pharmacovigilance, and Quality at Enzyvant Therapeutics, a biopharmaceutical company focused on developing transformative regenerative therapies as rapidly as possible. Kevin leads Enzyvant regulatory strategy and execution, including guiding the company’s lead asset, designated as a Regenerative Medicine Advanced Therapy (RMAT), to an FDA approval in 2021. He also is responsible for oversight of pharmacovigilance and quality systems at Enzyvant and partner organizations. Kevin brings more than a dozen years of biotech and pharmaceutical regulatory affairs experience to his role at Enzyvant. He was the head of Global Regulatory Affairs at Roivant Sciences and led development and successful filings for several therapies in the autoimmune and rare disease portfolio at Mallinckrodt Pharmaceuticals. He also served on global development teams for hepatitis B and C virus treatments at Gilead Sciences. Kevin received his BS in Biological Sciences from Cornell University, his PhD in Biochemistry from the University of Wisconsin–Madison, and completed a postdoctoral research fellowship in the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill. Kevin has completed his Regulatory Affairs Certification and has been an invited speaker at numerous national and international conferences.
Disclosure information not submitted.
Monday, September 12, 2022
3:30 PM – 4:30 PM MST